Anupam Rasayan outlines plan to scale Bliss GVS Pharma
In short
Anupam Rasayan India’s deputy CFO Vishal Thakkar said the company wants to grow its latest acquisition, Bliss GVS Pharma, in an interview with CNBC-TV18. The reported target is to double Bliss GVS Pharma’s revenue in three years.
This matters because it shows how the acquirer may try to expand the business after the deal. The reporting does not say how the company plans to do it or what risks could affect the target.
What the reporting says
Anupam Rasayan India’s deputy CFO, Vishal Thakkar, outlined plans to scale up the company’s latest acquisition, Bliss GVS Pharma, in an interview with CNBC-TV18. The publisher summary says the goal is to double Bliss GVS Pharma’s revenue in three years. The available reporting does not state the financing, execution steps, or any confirmed timetable beyond that target.
Why it matters
Anupam Rasayan India’s deputy CFO, Vishal Thakkar, said in a CNBC-TV18 interview that the company plans to scale up its latest acquisition, Bliss GVS Pharma, and aims to double its revenue over three years. The reporting gives no further details on the acquisition structure, capex, integration plan, or whether management has shared milestones. The market relevance is tied to the outlook for the acquired business and the parent company’s growth strategy.